Alzamend Neuro, Inc. Profile Avatar - Palmy Investing

Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, wh…

Biotechnology
US, Atlanta [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Alzamend Neuro, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ALZN's Analysis
CIK: 1677077 CUSIP: 02262M308 ISIN: US02262M4078 LEI: - UEI: -
Secondary Listings
ALZN has no secondary listings inside our databases.